We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Severe Anemia Associated with Increased Risk of Necrotizing Enterocolitis

By LabMedica International staff writers
Posted on 16 Mar 2016
Print article
Image: Histopathology comparing normal bowel at the left, to a bowel involved by necrotizing enterocolitis (NEC) at the right showing hemorrhagic necrosis, beginning in the mucosa and extending to involve the muscular wall, with the potential for perforation (Photo courtesy of the University of Utah School of Medicine).
Image: Histopathology comparing normal bowel at the left, to a bowel involved by necrotizing enterocolitis (NEC) at the right showing hemorrhagic necrosis, beginning in the mucosa and extending to involve the muscular wall, with the potential for perforation (Photo courtesy of the University of Utah School of Medicine).
Necrotizing enterocolitis (NEC) an acute, life-threatening, inflammatory disease occurring in the intestines of premature infants, is a leading cause of mortality among preterm infants with case-fatality rates of 20% to 30% yet the origin and development of NEC remains unclear.

There is conflicting data regarding the role of two risk factors, red blood cell (RBC) transfusion and anemia. Improving understanding of the role of RBC transfusion and anemia is important because more than half of among very low-birth-weight (VLBW) infants (1,500 grams or less) receive one or more transfusions during hospitalization.

Scientists at the Emory University School of Medicine (Atlanta, GA, USA) and their colleagues enrolled VLBW infants at three neonatal intensive care units in Atlanta within five days of birth. Infants received follow-up until 90 days, hospital discharge, transfer to a non-study-affiliated hospital, or death (whichever came first). Of 600 VLBW infants enrolled in the study 598 were evaluated from January 2010 to February 2014. The primary exposure was RBC transfusion. The secondary exposure was severe anemia, defined a priori as a hemoglobin level of 8 g/dL or less. Both exposures were evaluated as time-varying covariates at weekly intervals.

In the study 319(53%) infants received a total of 1,430 RBC transfusion exposures, 44 (7.4 %) infants developed NEC and 32 (5.4%) infants died (all causes). The unadjusted cumulative incidence of NEC at week eight among RBC transfusion-exposed infants was 9.9% versus 4.6% among those who were unexposed. In multivariable analysis, RBC transfusion in a given week was not significantly related to the rate of NEC. Based on evaluation of 4,565 longitudinal measurements of hemoglobin (median, 7 per infant), the rate of NEC was significantly increased among VLBW infants with severe anemia in a given week compared with those who did not have severe anemia.

The authors concluded that because severe anemia, but not RBC transfusion, was a risk factor for NEC in the study, preventing severe anemia may be more clinically important than minimizing RBC transfusion exposure as a strategy to decrease the risk of NEC. However, the effect of such a strategy on other important neonatal outcomes is unclear, and further study is needed. Ongoing clinical trials comparing liberal versus conservative transfusion practices may provide additional experimental data regarding the risks of both severe anemia and RBC transfusion to NEC. The study was published on March 1, 2016, in the Journal of the American Medical Association.

Related Links:

Emory University School of Medicine 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.